Many patent owners are interested in trying to draft a single
patent application that will serve them in several countries. This
is ambitious, since there are many differences between various
countries' patent systems, but perhaps not impossible. The
patent drafter just needs to be aware of and try to balance all the
different requirements in the single patent application. This
series of articles will outline some important considerations when
drafting a single patent application. In our first article
(available here), we reviewed the grace period provisions in the
U.S., Korea, China, and the European Patent Office
("EPO"). Since waiting for clinical trial data before
filing a patent application is not necessarily advisable, in this
article, we will look at how much data should be included on
filing. The article may be found on Finnegan's AIA blog.